Invivyd, Inc. (IVVD )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol IVVD
- Company Invivyd, Inc.
- Price $1.25
- Changes Percentage 17.92
- Change 0.19
- Day Low $1.04
- Day High $1.43
- Year High $5.1
- Year Low $0.36
- Market Cap $149,520,000
- Price Avg 50 EMA (D) $0.53
- Price Avg 200 EMA (D) $1.14
- Exchange NASDAQ
- Volume 95,791,851
- Average Volume 8,609,670
- Open $1.26
- Previous Close $1.06
- EPS -1.95
- PE -0.64
- Earnings Announcement 2025-03-26 12:30:00
- Shares Outstanding $119,616,000
Company brief: INVIVYD, INC. (IVVD )
- Healthcare
- Biotechnology
- Mr. Jeremy Gowler
- https://adagiotx.com
- US
- N/A
- 08-06-2021
- US00534A1025
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.